- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04391049
수술 후보가 아닌 진행성 식도암 환자를 위한 화학방사선 요법에 항암 바이러스 요법 Telomelysin™ 추가 테스트
OBP-301(Telomelysin™)의 확장 코호트와 수술 후보가 아닌 국소적으로 진행된 식도암 및 위식도암 환자를 위한 최종 화학방사선 요법을 사용한 1상 시험
This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.
연구 개요
상태
정황
- 임상 3기 위식도 접합부 선암종 AJCC v8
- 절제 불가능한 위식도 접합부 선암종
- 신보조 요법 후 치료 III기 위식도 접합부 선암종 AJCC v8
- 신보조 요법 후 치료 IIIA기 위식도 접합부 선암종 AJCC v8
- 신보조 요법 후 치료 IIIB기 위식도 접합부 선암종 AJCC v8
- 임상 II기 식도 선암종 AJCC v8
- 임상 병기 IIA 식도 선암종 AJCC v8
- 임상 3기 식도 선암종 AJCC v8
- 병리학적 병기 II 식도 선암종 AJCC v8
- 병리학적 병기 IIA 식도 선암종 AJCC v8
- 병리학적 병기 IIB 식도 선암종 AJCC v8
- 병리학적 3기 식도 선암종 AJCC v8
- 병리학적 병기 IIIA 식도 선암종 AJCC v8
- 병리학적 병기 IIIB 식도 선암종 AJCC v8
- 편평 세포 암종
- 임상 II기 위식도 접합부 선암종 AJCC v8
- 임상 병기 IIB 식도 선암종 AJCC v8
- 진행성 위식도 접합부 선암종
- 편평세포암
- 병리학적 3기 위식도 접합부 선암종 AJCC v8
- 병리학적 병기 IIIA 위식도 접합부 선암종 AJCC v8
- 병리학적 병기 IIIB 위식도 접합부 선암종 AJCC v8
- 신보조 요법 후 치료 III기 식도 선암종 AJCC v8
- 신보조 요법 후 치료 IIIA기 식도 선암종 AJCC v8
- 신보조 요법 후 치료 IIIB기 식도 선암종 AJCC v8
- 임상 병기 IIA 위식도 접합부 선암종 AJCC v8
- 임상 병기 IIB 위식도 접합부 선암종 AJCC v8
- 병리학적 2기 위식도 접합부 선암종 AJCC v8
- 병리학적 병기 IIA 위식도 접합부 선암종 AJCC v8
- 병리학적 병기 IIB 위식도 접합부 선암종 AJCC v8
- 진행성 식도 선암종
- 신보조 요법 후 치료 II기 식도 선암종 AJCC v8
- 신보조 요법 후 치료 II기 위식도 접합부 샘암종 AJCC v8
상세 설명
PRIMARY OBJECTIVE:
I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.
SECONDARY OBJECTIVES:
I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.
II. To assess the number of clinical complete responses (cCR).
III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.
EXPLORATORY OBJECTIVE:
I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.
OUTLINE:
This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.
Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Duarte, California, 미국, 91010
- City of Hope Comprehensive Cancer Center
-
South Pasadena, California, 미국, 91030
- City of Hope South Pasadena
-
Upland, California, 미국, 91786
- City of Hope Upland
-
-
Florida
-
Tampa, Florida, 미국, 33612
- Moffitt Cancer Center
-
-
Kansas
-
Fairway, Kansas, 미국, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, 미국, 66160
- University of Kansas Cancer Center
-
Westwood, Kansas, 미국, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, 미국, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, 미국, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, 미국, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, 미국, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, 미국, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, 미국, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, 미국, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Houston, Texas, 미국, 77030
- UT MD Anderson Cancer Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration
- Gastroesophageal junction tumors must be Siewert type I/II
-
Required diagnostic workup for study entry:
- History/physical examination prior to registration
- Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
- Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
- Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
- Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration
-
Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)
-
Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
-
AST/ALT ≤ 2.5 x ULN
-
Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;
-
Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures
-
Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months
-
Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device
-
The patient must provide study-specific informed consent prior to study entry
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial
Exclusion Criteria:
-
Definitive clinical or radiologic evidence of metastatic disease including:
- Positive malignant cytology of the pleura, pericardium or peritoneum
- Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
- Tracheoesophageal fistula
- Radiographic evidence of distant organ involvement
- Non-regional lymph nodes that cannot be contained within a radiation field
-
More than 1 esophageal lesion
-
Prior systemic chemotherapy for the study cancer
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis
-
For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse
-
Uncontrolled diabetes
-
Infection requiring IV antibiotics at the time of registration
-
Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry
-
Received live vaccine within 30 days prior to registration
-
Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab
-
Breast feeding females
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Treatment (OBP-301, carboplatin, paclitaxel, radiation)
Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity. |
Intravenously (IV)
다른 이름들:
Intravenously (IV)
다른 이름들:
Daily fractions
다른 이름들:
Intra-tumoral injection
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
기간: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:
If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL). |
From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
1 년과 2 년에 살아있는 참가자 수
기간: 1 년과 2 년
|
1 년과 2 년
|
|
|
Number of Participants by Highest Grade Adverse Event Reported
기간: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
|
Number of Participants With Clinical Complete Response (cCR)
기간: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:
|
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
|
Number of Participants Alive Without Progression at 1 and 2 Years
기간: At 1 and 2 years
|
Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease. |
At 1 and 2 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NRG-GI007
- U10CA180868 (미국 NIH 보조금/계약)
- NRG-GI007 (기타 식별자: CTEP)
- NCI-2020-02320 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- NRG-GI007 (기타 식별자: NRG Oncology)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .